Considering the proposed co-regulatory relationship between KDM3A, KDM4B, and FOXA1, which facilitates a cancer phenotype in ER-positive BC, these data together suggest that targeting KDM3A and KDM4B simultaneously may be an efficacious therapeutic strategy. Here, FOXA1 is linked to breast cancer.